Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.742 |
---|---|
High | 0.76 |
Low | 0.725 |
Bid | 0.70 |
Offer | 0.7494 |
Previous close | 0.75 |
Average volume | 102.51k |
---|---|
Shares outstanding | 3.40m |
Free float | 2.22m |
P/E (TTM) | -- |
Market cap | 2.55m USD |
EPS (TTM) | -27.55 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
- Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
- Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
- Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
- Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
- Altamira Therapeutics Provides Business Update
More ▼